Flamel Technologies (FLML): Sodium Oxybate Getting Back On Track - Needham

September 27, 2016 6:20 AM EDT
Get Alerts FLML Hot Sheet
Price: $12.22 -0.65%

Rating Summary:
    6 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade FLML Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Leerink Partners analyst, Jason Gerberry reiterated his Outperform rating on shares of Flamel Technologies (NASDAQ: FLML) after the company highlighted that the pivotal Phase 3 study (REST-ON) for the company's once-nightly sodium oxybate (similar to JAZZ’s Xyrem) commenced after a several month delay.

At the event, mgmt emphasized 3 key features it believes will differentiate m-SXB:

1) once-nightly dosing vs. Xyrem's twice-nightly dosing.

2) tamper-resistant packaging - FLML plans to package m-SXB in child resistant packaging and emphasized QD dosing mitigates the issue of having an unattended dose on the pts nightstand

3) tolerability benefit - mgmt believes less water consumed with QD dosed product could cut down on the frequency of nocturnal enuresis (bed wetting).

Key upcoming events for FLML include: (1) possible update on Xyrem 2.0 by end-2016, per JAZZ; (2) Xyrem patent updates over the next 12 months.

No change to the price target of $16.

For an analyst ratings summary and ratings history on Flamel Technologies click here. For more ratings news on Flamel Technologies click here.

Shares of Flamel Technologies closed at $13.36 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Management Comments

Related Entities

Needham & Company

Add Your Comment